Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

7.41USD
4:00pm EDT
Change (% chg)

$0.13 (+1.79%)
Prev Close
$7.28
Open
$7.34
Day's High
$7.43
Day's Low
$7.29
Volume
22,462
Avg. Vol
51,262
52-wk High
$15.20
52-wk Low
$5.96

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Reports Q2 Loss Per Share $0.37
Thursday, 1 Aug 2019 04:01pm EDT 

Aug 1 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND UNVEILS POSITIVE RESULTS FROM PILOT EFFICACY STUDY OF PARVOVIRUS MONOCLONAL ANTIBODY.Q2 LOSS PER SHARE $0.37.Q2 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.TARGETING APPROVAL OF PARVOVIRUS MONOCLONAL ANTIBODY PRODUCT CANDIDATE BY LATE 2020, OR EARLY 2021.RECORDED $1.2 MILLION IN NET PRODUCT REVENUES FOR MIRATAZ FOR Q2.  Full Article

Kindred Biosciences Says Notified By Contract Manufacturer That FDA Has Follow Up Questions Following March Inspection
Thursday, 16 May 2019 04:30pm EDT 

May 16 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES-NOTIFIED BY CONTRACT MANUFACTURER OF API DIPYRONE THAT FDA CENTER FOR VETERINARY MEDICINE HAS FOLLOW UP QUESTIONS, FOLLOWING MARCH INSPECTION.KINDRED - ONCE RESPONSES ARE PROVIDED BY API MANUFACTURER, CO INTENDS TO REACTIVATE NADA FOR DIPYRONE INJECTION FOR CONTROL OF PYREXIA IN HORSES.KINDRED BIOSCIENCES INC - FDA HAS GRANTED A SHORTENED TIMELINE OF 135 DAYS FOR REVIEW OF NADA.KINDRED BIOSCIENCES INC - WILL PROVIDE AN UPDATE ON TIMING OF DIPYRONE INJECTION'S EXPECTED APPROVAL DURING ITS Q2 2019 RESULTS..  Full Article

Kindred Biosciences Q1 Loss Per Share $0.42
Thursday, 9 May 2019 04:01pm EDT 

May 9 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.42.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.KINDRED BIOSCIENCES - BELIEVES EXISTING CASH, CASH EQUIVALENTS, OTHERS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH EARLY 2021..  Full Article

Kindred Biosciences Announces Fourth Quarter And Full Year 2018 Financial Results
Wednesday, 6 Mar 2019 04:01pm EST 

March 6 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.QTRLY NET PRODUCT REVENUES $1.3 MILLION VERSUS NO PRODUCT REVENUES FOR THE SAME PERIOD LAST YEAR.  Full Article

Kindred Biosciences Says Public Offering Of 4.22 Mln Common Shares Priced At $9.50/Share
Friday, 18 Jan 2019 09:31am EST 

Jan 18 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.22 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.  Full Article

Kindred Biosciences Announces Q3 Loss Per Share $0.39
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.39.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.  Full Article

Kindred Biosciences Announces Positive Results From Pilot Effectiveness Study
Tuesday, 30 Oct 2018 04:01pm EDT 

Oct 30 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PILOT EFFECTIVENESS STUDY OF ITS FULLY CANINIZED IL-31 ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS IN DOGS AND ISSUANCE OF U.S. PATENT.KINDRED BIOSCIENCES INC - STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS VERSUS PLACEBO WAS ACHIEVED ACROSS ALL DOSE GROUPS.KINDRED BIOSCIENCES INC - U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT (PATENT NO. 10,093,731) FOR KINDREDBIO'S ANTI-IL31 ANTIBODY.KINDRED BIOSCIENCES INC - BASED ON A PRELIMINARY REVIEW OF SAFETY DATA, IL-31 DRUG APPEARS TO BE WELL TOLERATED.  Full Article

Kindred Biosciences Announces Pricing Of Public Offering
Wednesday, 20 Jun 2018 09:10am EDT 

June 20 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.  Full Article

Kindred Biosciences Q4 Loss Per Share $0.35
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.35.  Full Article

KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
Thursday, 21 Dec 2017 08:02am EST 

Dec 21 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™.KINDRED BIOSCIENCES INC - EMA HAS ACCEPTED SUBMISSION FOR REVIEW, WITH OFFICIAL ACCEPTANCE DATE OF DECEMBER 21, 2017.KINDRED BIOSCIENCES INC - EXECUTED NATIONAL DISTRIBUTION DEALS WITH MWI VETERINARY SUPPLY CO. & DIRECT VET MARKETING, INC. D/B/A VETS FIRST CHOICE.  Full Article